Monoclonal antibodies in hematological malignancies

Perla R Colunga-Pedraza; Julia Esther Colunga-Pedraza; Rosa Elena Lozano-Morales; Andrea Cecilia Garza-Acosta; Olga G Cantú-Rodríguez

2017, Number 1

<< Back Next >>

Rev Hematol Mex 2017; 18 (1)

Monoclonal antibodies in hematological malignancies

Colunga-Pedraza PR, Colunga-Pedraza JE, Lozano-Morales RE, Garza-Acosta AC, Cantú-Rodríguez OG

Full text

How to cite this article

Language: Spanish
References: 0
Page: 16-25
PDF size: 131.63 Kb.

ABSTRACT

Monoclonal antibodies are a successful therapeutic choice for a wide range of diseases, including hematological malignancies. Targeted therapy has been used in combination with other drugs or as monotherapy, proffering an important improvement in quality of life of patients and demonstrating a tolerable profile of adverse effects due to limited toxicity. Currently have been approved a large amount of monoclonal antibodies and several number of molecules are undergoing clinical evaluation. The present review sets out their application in hematological diseases.